Statistics in Biopharmaceutical Research

Papers
(The H4-Index of Statistics in Biopharmaceutical Research is 10. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2021-06-01 to 2025-06-01.)
ArticleCitations
Composite Endpoints in Cardio-Renal Clinical Outcome Trials26
Predicting Probability of Success for Phase III Trials via Propensity-Score-Based External Data Borrowing19
U-MET: Utility-Based Dose Optimization Approach for Multiple-Dose Randomized Trial Designs19
Treatment Selection at Interim Analysis Based on a Correlated Early Endpoint in Adaptive Two-Stage Trials with a Primary Endpoint Based on Count Data18
DODII: Bayesian Dose Optimization Design for Randomized Phase II Trials15
Use of Nonconcurrent Common Control in Master Protocols in Oncology Trials: Report of an American Statistical Association Biopharmaceutical Section Open Forum Discussion14
Missing Data Imputation for a Multivariate Outcome of Mixed Variable Types13
Statistical Inference of the Probability of Passing the USP Dissolution Test13
We Need Subject Matter Expertise to Choose and Identify Causal Estimands: Comment on “Estimands for Recurrent Event Endpoints in the Presence of a Terminal Event”11
Some Multiplicity Adjustment Procedures for Clinical Trials with Sequential Design and Multiple Endpoints10
Bayesian and Frequentist Approaches to Rescuing Disrupted Trials: A Report from the NISS Ingram Olkin Forum Series on Unplanned Clinical Trial Disruptions10
The current landscape of HTA framework and key challenges10
Joint Analysis of Longitudinal Ordinal Categorical Item Response Data and Survival Times with Cure Fraction10
0.041448831558228